Apatide 60mg Tablet

Like other anticancer medicines, Apatide 60mg Tablet has mild to severe side effects. These are undesired symptoms observed in the body after taking this tablet. Usually, they disappear with time as the body adjusts to the medicine. These adverse effects don't need special medical attention, but if you observe them continually, talk to your medical expert. Some of them are listed below:

Mild side effects:

Fatigue
Diarrhea
Vomiting
Nausea
Joint and muscle pain
High blood pressure
High blood sugar
Skin rashes and itching
Weight loss and loss of appetite
Hot flushes
Tiredness and dizziness

Severe Side effects:

Decrease in blood count (Anemia)
Leukopenia
Increase in cholesterol level
Cardiovascualr disorders
Seizures
Fractures in bones
Swelling in hand and feet

Apatide 60mg Tablet is a prescription-based anticancer drug that should be administered orally. It is advised to take this tablet after consulting your healthcare expert.

Apatide 60mg Tablet belongs to the class of selective androgen receptor (AR) inhibitor that binds to the androgen receptor binding domain. The multiplication of prostate cancer relies on the sex hormone, androgen. In some cases, cancer becomes resistant to standard hormonal therapies, androgen receptors function continuously and promote cancer growth. Apatide blocks the signaling pathway, DNA binding, AR-mediated transcription, and protein transportation in the nucleus, which leads to the replication of the cancer cells. Apatide 60mg Tablet inhibits the receptor activation and prevents them from binding to androgen. In that way, it lowers the growth and multiplication of the cancer cells.

It is advised not to miss any scheduled dosage of Apatide 60mg Tablet. In case you miss a dose, consult your doctor immediately. Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

Apatide 60mg Tablet is not recommended in patients with a history of seizures, any brain injury, or a recent stroke (within one year).

Inform your doctor if you have a history of cardiovascular problems before taking Apatide 60mg Tablet.

Your healthcare expert must measure your blood sugar & pressure, potassium level, and liver function tests at regular intervals. Taking the Apatide 60mg Tablet can cause fluctuations in their levels.

It is recommended to inform your doctor if you are taking any prescribed and non-prescribed medications, nutritional or vitamin supplements, or herbal products. These drugs can interact with Apatide 60mg Tablet and may result in some severe side effects.

Your healthcare provider will decide how much you take and how often you need Apatide 60mg Tablet. You are advised to follow the prescription strictly.

Do not stop taking Apatide 60mg Tablet until your doctor says to do so.

Using Apatide 60mg Tablet causes light sensitivity. Use sunscreen before exposing to direct sunlight.

Use reliable methods of birth control and contraceptive pills to delay pregnancy while under treatment with Apatide 60mg Tablet. Discuss with your healthcare expert the risks and benefits of taking this medicine if you want to conceive in the future.

Birtle, A. J., Formisano, L., Descamps, V., Weisenseel, P., & Vilaseca, A. (2024). Early identification and management of patients with rash on apalutamide. Oncology and Therapy, 12(3), 609-620.
Chi, K. N., Chowdhury, S., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., & Agarwal, N. (2024). Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. Journal of Clinical Oncology, 39(20), 2294-2303.
Shen, J., Chowdhury, S., Agarwal, N., Karsh, L. I., Oudard, S., Gartrell, B. A., & Graff, J. N. (2024). Apalutamide efficacy, safety, and well-being in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. British Journal of Cancer, 130(1), 73-81.
Small, E. J., Chi, K. N., Chowdhury, S., Bevans, K. B., Bhaumik, A., Saad, F., & Agarwal, N. (2025). Post hoc analysis of rapid and deep prostate-specific antigen decline and patient-reported health-related quality of life in SPARTAN and TITAN patients with advanced prostate cancer. European Urology Oncology, 7(4), 844-852.
Sopeña Sutil, R., Silva Ruiz, J., Garcia Gomez, B., Romero- Otero, J., Garcia-Gonzalez, L., Duarte Ojeda, J. M., & Rodriguez Antolin, A. (2024). Seizures and neuropsychiatric toxicity in patients with non-metastatic CRPC treated with new antiandrogens: systematic review and meta-analysis. Oncology Research and Treatment, 44(4), 154-163.